Krishnan Nandabalan, Ph.D., is the co-founder, Chief Scientific Officer and President of BioXcel Corporation, a company that develops cloud-based big data platforms and transformative patient treatments. He brings over two decades of experience across multiple functions in the pharmaceutical and biotechnology industries, including research & development, operations, and business development. He has extensive experience in setting up processes for high throughput discovery and data mining. He currently heads the Big Data Innovation Lab at BioXcel and is involved in developing and utilizing proprietary algorithms and machine learning for validating novel targets and drugs in orphan diseases and major therapeutic areas such as immuno-oncology. Previously, Dr. Nandabalan served as the Vice President of Corporate Development at Genaissance Pharmaceuticals, a company that applied population genomics to improve the development, marketing and prescribing of drugs. Prior to this, he served as Group Leader of the Functional Genomics Group at CuraGen Corporation, a company that developed novel therapeutics for the treatment of cancer. Dr. Nandabalan has 12 issued patents and has published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India and was a Post-Doctoral Fellow at the University of Kentucky and Yale University.